Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70180 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Katherine R Tuttle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, DC, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Renal Insufficiency, Chronic, Diabetic Nephropathies. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer AG, Bayer.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes. However, people with T1D were largely excluded from these CKD therapeutic development programmes. Recent treatment advancements for people with T2D include the introduction of sodium–glucose cotransporter 2 inhibitors, a nonsteroidal mineralocorticoid antagonist, and glucagon‐like peptide‐1 receptor agonists. The development and progression of CKD in people with T1D are driven by a constellation of risk factors such as hyperglycemia, hypertension, obesity, and others that share common mechanistic links with T2D. As such, a compelling rationale exists for focused studies of these therapeutic classes for the treatment of CKD in T1D. Additionally, care provided by a coordinated team of primary care clinicians, endocrinologists, nephrologists, and cardiologists is central to therapeutic implementation. There is a major unmet need for improved treatments for CKD in people with T1D. Ongoing and future studies will help to establish whether proven therapies for CKD in T2D are also safe and efficacious in people with T1D. Coordinated, cross‐specialty approaches to awareness, detection, and intervention for CKD are also needed to improve kidney, cardiovascular, and survival outcomes in people with T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, DC, USA.
- Nephrology Division, Kidney Research Institute, University of Washington School of Medicine, Seattle, Washington, DC, USA.
- Peking University People's Hospital, Peking University Diabetes Centre, Beijing, China.
- Department of Endocrinology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.
- Breakthrough T1D, New York, New York, USA.
ORCID-Profile: Katherine R Tuttle, Linong Ji, Chantal Mathieu
Förderung
- Bayer AG
- Bayer
Zitieren
APA
Tuttle, K. R., Ji, L., Mathieu, C., & Rosen, J. (2026). Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70180
Vancouver
Tuttle KR, Ji L, Mathieu C, Rosen J. Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70180
BibTeX
@article{Tuttle2026,
author = {Tuttle, Katherine R and Ji, Linong and Mathieu, Chantal and Rosen, Jonathan},
title = {Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70180}
}
EUVIMED